Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection

被引:16
作者
Perdona, Sisto [1 ]
Di Lorenzo, Giuseppe [2 ]
Autorino, Riccardo [3 ]
Buonerba, Carlo [2 ]
De Sio, Marco [3 ]
Setola, Sergio Venanzio [4 ]
Fusco, Roberta [4 ]
Ronza, Francesco Michele [5 ]
Caraglia, Michele [6 ]
Ferro, Matteo [7 ]
Petrillo, Antonella [4 ]
机构
[1] Fdn G Pascale, Ist Nazl Tumori, Urol Sect, Naples, Italy
[2] Univ Naples Federico II, Dept Endocrinol & Med Oncol, Genitourinary Canc Sect, Naples, Italy
[3] Univ Naples 2, Urol Sect, Naples, Italy
[4] INT Fdn G Pascale, Dept Radiol, Naples, Italy
[5] Univ Naples 2, Dept Radiol, Naples, Italy
[6] Univ Naples 2, Dept Biochem & Biophys, Naples, Italy
[7] Univ Naples Federico II, Dept Urol, Naples, Italy
关键词
Magnetic resonance; Spectroscopy; Prostate cancer; BIOPSY; DIAGNOSIS;
D O I
10.1016/j.urolonc.2011.07.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The use of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) have emerged as a valid diagnostic tools for prostate cancer (CaP). Methods: Men with PSA levels below 10 neml were enrolled in a prospective cohort study and underwent combined MRSI and DCE-MRI and transrectal ultrasound-guided prostate biopsy. Imaging was performed using a 1.5 T MR scanner (Symphony TIM; Siemens, Erlangen, Germany) with an endorectal coil (Medrad; Pittsburg, PA), inflated with 60 cc of air. Three-dimensional magnetic resonance spectroscopic data were acquired by using water and a lipid-suppressed double-spin-echo point-resolved spectroscopy sequence, which was optimized for quantitative detection of both choline and citrate. Dynamic contrast-enhanced MRI sequences were obtained with 3D T1-weighted FLASH images before and during rapid bolus administration of intravenous paramagnetic contrast medium gadoteric acid. Specificity, sensitivity, positive predictive value, negative predictive value, and accuracy were computed considering patients, each of the 2 lobes, each of the 6 sextants, and each 12th part of the prostate gland as single measurements. Results: Overall, 106 patients were included in the analysis. Median age was 65.9 years (range, 61.2-70.5 years) and median PSA level at study entry was 7.1 ng/ml (range, 2.5-9.9). CaP was detected at biopsy in 24 patients (22.6 % of the population) with a median Gleason score of 8 (range 4-10). Diagnostic accuracy of combined MRSI and DCE-MRI was 85%, sensitivity was 71%, and specificity was 48%, considering patients as single measurements, with a negative predictive value of 91%, but a positive predictive value of only 19%. Positive predictive value of the examination improved to 25% for patients who repeated biopsy. Conclusions: Although this study confirms the potential usefulness of MRI for the diagnosis of CaP, the positive predictive value obtained was unacceptably low due to the high number of false positives recorded. Nevertheless, the high negative predictive value of the examination may serve to avoid unnecessary biopsies. Future research should be directed at assessing the value of combining MRI-based techniques with novel biochemical markers for the diagnosis of CaP in patients with low PSA levels. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 14 条
[1]   Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging [J].
Beyersdorff, D ;
Taupitz, M ;
Winkelmann, B ;
Fischer, T ;
Lenk, S ;
Loening, SA ;
Hamm, B .
RADIOLOGY, 2002, 224 (03) :701-706
[2]  
Carlani M, 2008, RADIOL MED, V113, P670, DOI 10.1007/s11547-008-0271-8
[3]   Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging [J].
Delongchamps, Nicolas Barry ;
Rouanne, Mathieu ;
Flam, Thierry ;
Beuvon, Frederic ;
Liberatore, Mathieu ;
Zerbib, Marc ;
Cornud, Francois .
BJU INTERNATIONAL, 2011, 107 (09) :1411-1418
[4]   Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review [J].
Eichler, K ;
Hempel, S ;
Wilby, J ;
Myers, L ;
Bachmann, LM ;
Kleijnen, J .
JOURNAL OF UROLOGY, 2006, 175 (05) :1605-1612
[5]  
Kawachi MH, 2010, J NATL COMPR CANC NE, V8, P240, DOI 10.6004/jnccn.2010.0016
[6]   Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - Correlation with biopsy and histopathology [J].
Kozlowski, Piotr ;
Chang, Silvia D. ;
Jones, Edward C. ;
Berean, Kenneth W. ;
Chen, Henry ;
Goldenberg, S. Larry .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2006, 24 (01) :108-113
[7]   Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.1-cm(3)) spatial resolution [J].
Kurhanewicz, J ;
Vigneron, DB ;
Hricak, H ;
Narayan, P ;
Carroll, P ;
Nelson, SJ .
RADIOLOGY, 1996, 198 (03) :795-805
[8]   Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3 [J].
Perdona, Sisto ;
Cavadas, Vitor ;
Di Lorenzo, Giuseppe ;
Damiano, Rocco ;
Chiappetta, Gennaro ;
Del Prete, Paola ;
Franco, Renato ;
Azzarito, Giuseppina ;
Scala, Stefania ;
Arra, Claudio ;
De Sio, Marco ;
Autorino, Riccardo .
EUROPEAN UROLOGY, 2011, 59 (01) :81-87
[9]   MR-guided biopsy of the prostate:: An overview of techniques and a systematic review [J].
Pondman, Kirsten M. ;
Futterer, Jurgen J. ;
ten Haken, Bennie ;
Kool, Leo J. Schultze ;
Witjes, J. Alfred ;
Hambrock, Thomas ;
Macura, Katarzyna J. ;
Barentsz, Jelle O. .
EUROPEAN UROLOGY, 2008, 54 (03) :517-527
[10]   Repeat prostate biopsy-when, where, and how [J].
Presti, Joseph C., Jr. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (03) :312-314